Skip to content

Building a Healthier Future: Designing for AI Health Equity – NAACP

Join our community of over 2 million activists across the nation fighting for change and for justice.
So glad to be a part of this great organization. Setting an example for my kids. Being a part of the change I want to see in the world. Starting in my own community!
Join our community of over 2 million activists across the nation fighting for change and for justice.
Fighting racial injustice by building Black political, social, and economic power
A world-class education for all students
An environmental, social, and economic revolution
Mobility and a thriving Black economy
An inclusive culture of health and equitable social health systems
Support for young leaders and change agents
Fair and just representation for all by standing up for our rights in the courts and in Congress
We work to turn the Black community's priorities into public policy through the legislative process.
As artificial intelligence (AI) rapidly transforms healthcare delivery, diagnostics, and treatment models, the report highlights the promises of Health AI and calls for intentional design and governance to ensure these technologies embed bold equity principles. Building a Healthier Future focuses on some of the critical challenges and opportunities that are emerging as AI evolves and will play an ever-increasing role in health care. 
The NAACP, in partnership with Sanofi through the ACE Your Health Initiative, calls for an equity-first, human-centered approach to developing and deploying AI in healthcare. The new white paper, Building a Healthier Future: Designing for AI Health Equity, outlines a compelling framework to ensure AI use in healthcare strengthens, rather than undermines, equity in the healthcare system.
The full white paper is organized around six thematic examples that illustrate the dynamic interactions between health, equity, and AI. These examples illustrate some of the ways in which the adoption of AI in health-related settings among a diversity of stakeholders provokes important social and ethical questions about the future of health care.
In a typical scenario, a patient might input their symptoms or lab results in a chatbot to generate a diagnosis, a second opinion, or ideas for a treatment regimen. While some doctors note that this suggests a level of patient engagement in the management of their own health — an activity they welcome — they also explain how AI chatbots can promote confusion when the generated outputs are inaccurate or not applicable to the patient.
Users’ engagement with AI chatbots are quite different than their engagement with more conventional informational tools like the Google search engine. A surging number of people are turning to AI chatbots for companionship and therapeutic relief. 
Safety-net providers identify AI as a potential remedy, noting that the technology’s ability to help collect and analyze digital and medical biomarkers while the patient is away from the clinic could be transformational. Safety-net providers also express concerns about AI, including insufficient technical and financial resources to support AI training and the building of the technical infrastructure required to integrate AI into the clinical workflow.
Most clinicians understand the potential value of large language models (LLMs) in health care but voice concerns about the ability of these systems to generate outputs that are based on clinically validated evidence. 
Although LLMs are being used to support diagnostic reasoning and offer mental health support to those in need, there are risks associated with the use of LLMs in health care, including the tendency of these systems to “hallucinate,” that is, to make things up and add in bias against populations that may not be adequately represented in the datasets and training models used to develop frontier LLMs.
Synthetic data is artificially generated data that mimics real-world data but is not collected from actual people or real environments. The core problem synthetic data solves is non-generalizability. AI models trained on narrow or biased datasets consistently underperform across demographic subgroups, care settings, and devices, which systematically amplifies existing health disparities (Gallon, 2024; Daneshjou et al., 2022)
While synthetic data offers powerful tools for enhancing equity and privacy, it is not immune to reproducing or even amplifying biases that exist in source datasets or in the design and deployment processes.
Pharmaceutical companies face mounting expectations to accelerate research and development timelines, diversify clinical trials, and ensure AI-enabled tools perform equitably across populations and geographies. Evidence-based practices can align innovation with equity imperatives across the development lifecycle.
One of the most enduring problems in the execution of clinical trials is the lack of diversity in participant populations (Oertelt-Prigione & Turner, 2024). Inadequate race and ethnic representation in clinical trials limits the ability to detect notable differences between demographic groups with regards to an intervention’s safety or efficacy.
Even as AI promises to deliver more personalized and predictive healthcare, the perils — both known and unknown — require attention to ethics, safety, and equity.
© 2026 NAACP. All Rights Reserved.
You can become a Champion for Change and receive a t-shirt with your monthly gift of $19 a month or more right now.

source

author avatar
punkinpatchmedia@gmail.com

Leave a Reply

Your email address will not be published. Required fields are marked *